Pricing
  1. JP-listed companies
  2. TMS Co., Ltd
  3. Financials
  4. Cash from financing

TMS Co., Ltd【JP:4891】

Market cap
¥6.2B
P/E ratio
Timbs Inc. develops anti-inflammatory drugs from black mold compounds, targeting diseases like stroke and inflammatory conditions through partnerships with major pharmaceutical companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from financing (Million JPY)YoY (%)
Dec 31, 2025641+69597.06%
Feb 28, 20251-99.87%
Feb 29, 2024688-59.25%
Feb 28, 20231,689+585.17%
Feb 28, 2022246-77.62%
Feb 28, 20211,101

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)